Keyword: Aldeyra Therapeutics

The results tee Aldeyra up to move the aldehyde-binding small molecule into phase 3 next year.

Aldeyra Therapeutics and Janssen inked a pact to develop new drugs for inflammatory diseases.

Aldeyra says it has seen “statistically and clinically significant improvements” in a midstage trial for its experimental eye med ADX-102, although not all data points were positive.

A phase 2b trial of Aldeyra Therapeutics’ allergic conjunctivitis candidate ADX-102 has missed its primary endpoint.